New Blood Test Could Detect Thousands of Genetic Changes During Pregnancy

A new blood test for pregnant women could revolutionize the early detection of genetic abnormalities in the unborn child. According to scientists, the test has the potential to identify thousands of serious genetic abnormalities as early as during pregnancy—thereby significantly reducing the need for invasive diagnostic procedures.

The method was presented at the conference of the European Society of Human Genetics in Gothenburg. The approach is based on a modern form of genetic analysis that examines tiny fragments of fetal DNA in the mother’s blood. This DNA originates from the developing fetus and circulates naturally in the mother’s bloodstream.

Non-invasive Fetal Sequencing as a New Technology

The method, known as non-invasive fetal sequencing (NIFS), uses advanced sequencing technologies to indirectly analyze the fetus’s entire genetic material. This allows for the identification of genetic variants in thousands of genes—a significantly broader spectrum than in previous prenatal tests.

Until now, non-invasive blood tests have primarily focused on a few chromosomal abnormalities, such as Down syndrome. The new technique goes much further and could theoretically detect nearly all known genetic abnormalities that are also examined in expanded newborn screenings.

Wide Range of Possible Diagnoses

In initial validation studies, researchers were able to detect a variety of genetic disorders, including Noonan syndrome, CHARGE syndrome, Stickler syndrome, and achondroplasia. In total, variants in approximately 23,000 genes were analyzed. These genetic disorders and syndromes belong to various groups of rare diseases that often become apparent before or shortly after birth and can affect different organ systems. Noonan syndrome, for example, is a genetic syndrome frequently associated with heart defects, growth delays, and characteristic physical features. In some cases, learning difficulties may also occur. However, the severity varies greatly, ranging from relatively mild symptoms to more severe health impairments.

CHARGE syndrome is a rare genetic disorder that can affect multiple parts of the body. The name is derived from typical features, including eye abnormalities (coloboma), heart defects, a narrowing or closure of the posterior nasal openings, growth and developmental delays, and ear abnormalities that are often associated with hearing impairments. Affected children often require comprehensive medical care, especially during the first years of life.

Stickler syndrome primarily affects the connective tissue and may be associated with eye problems such as an increased risk of retinal detachment, joint hypermobility, facial features, and hearing impairments. Here, too, the severity can vary greatly. Early diagnosis can help identify potential complications in a timely manner and treat them effectively.

Achondroplasia is the most common genetic form of short stature. It results from a mutation in the FGFR3 gene, which affects bone growth. Typical features include shortened arms and legs with a largely normal torso length. Intellectual development is generally not impaired. From a medical perspective, the early detection of potential orthopedic or neurological complications is particularly important.

According to the researchers involved, the new sequencing technology could also enable the early detection of rare genetic disorders in the future—especially those where an early diagnosis can significantly influence the course of pregnancy, birth planning, or the medical care of the newborn. Early knowledge of genetic changes could make it possible to better plan births, provide specialized care immediately after birth, or, in certain cases, prepare therapeutic measures as early as during pregnancy.

Comparison with Invasive Procedures

Currently, procedures such as amniocentesis or chorionic villus sampling are considered the gold standard in prenatal diagnostics. Both methods allow for direct genetic analysis of the fetus by extracting either amniotic fluid (amniocentesis) or tissue from the placenta (chorionic villus sampling). This allows for the highly reliable detection of chromosomal abnormalities and numerous genetic disorders. Despite their high diagnostic accuracy, however, these procedures are invasive. This means that a medical intervention in the uterus is necessary, which—although rare—can be associated with risks. These include, among other things, infections, bleeding, or, in a small percentage of cases, pregnancy complications, including an increased risk of miscarriage.

Amniocentesis is usually performed between the 15th and 20th week of pregnancy. Under ultrasound guidance, a small amount of amniotic fluid containing fetal cells is extracted using a thin needle. These cells are then genetically analyzed in the laboratory. Although the method has been established for decades and is highly accurate, many expectant parents find the procedure stressful—both physically and emotionally. The situation is similar with chorionic villus sampling, which can usually be performed earlier in pregnancy. Here, too, tissue is collected that is genetically identical to the fetus. The advantage lies in early diagnosis; the disadvantage is also the invasive nature of the procedure.

Against this backdrop, the new blood test is gaining importance. Since only a simple blood sample from the mother is required, there is no need for any direct intervention in the pregnancy. The fetal DNA fragments circulating in the mother’s blood can be analyzed without touching the fetus itself. This significantly reduces the medical risk while simultaneously allowing for the collection of a very broad spectrum of genetic information. Should the method’s high diagnostic accuracy be confirmed in larger studies, it could be used as a first-line screening tool in the future—particularly in cases where a safe and non-invasive evaluation is desired before invasive diagnostics are even considered.

Results of Previous Studies

In a study involving 565 pregnancies, the researchers compared the new blood test with established invasive procedures. The samples were analyzed on average during the 17th week of pregnancy, a time when comprehensive genetic assessments are already possible. The results showed that the method was able to detect approximately 95 to 99 percent of the genetic variants that were also identified through amniocentesis or chorionic villus sampling. Both common and rare variants that may be relevant to various genetic disorders were taken into account.

For clinically significant variants, the concordance rate was even over 97 percent. This category includes genetic changes that, according to the current state of medical knowledge, are associated with an actual disease or an increased risk and are therefore particularly important for diagnosis and counseling. The high accuracy is especially remarkable given that the test is based on cell-free fetal DNA in maternal blood, which is present only in very small quantities. Reliable analysis therefore requires complex bioinformatic methods to clearly distinguish fetal DNA from maternal DNA. Overall, the results to date point to very high diagnostic performance for a non-invasive approach, which, however, must be further confirmed in larger studies before broader clinical use.

A Potential Shift in Prenatal Diagnostics, but With Challenges and Risks

Experts view the development as a significant advance in reproductive medicine. Geneticist Dr. Christopher Whelan emphasized that the test could theoretically be used as a first-line screening tool, particularly when abnormalities are detected during ultrasound examinations. Independent experts also spoke positively about the technical achievement. Professor Alexandre Reymond described the ability to sequence the fetal genome without direct sample collection as a significant breakthrough. At the same time, however, there are also critical voices. Some experts warn that comprehensive genetic analysis could potentially create uncertainty—especially when variants are discovered whose clinical significance is still unclear. This could lead to unnecessary anxiety among parents and contribute to difficult decisions during pregnancy.

The new blood test impressively demonstrates how rapidly prenatal diagnostics are advancing through modern sequencing technologies. The ability to detect thousands of genetic disorders early and non-invasively could fundamentally change medical care during pregnancy. In particular, the lower risk compared to invasive procedures, as well as the significantly broader genetic coverage, open up new possibilities for earlier and more comprehensive diagnostics.

At the same time, this technological development brings with it considerable ethical and medical challenges. A key problem is that not all identified genetic variants can be unambiguously interpreted. Many genetic changes are so-called variants of uncertain significance, for which it cannot currently be said with certainty whether they actually lead to a disease or remain clinically insignificant. Such findings can lead to uncertainty and result in difficult decisions for expectant parents. Added to this is the psychological strain of being confronted with a very large amount of genetic information. While earlier tests focused on a few, clearly defined diseases, the new method opens up a significantly broader spectrum of potential findings. On the one hand, this can be medically valuable; on the other hand, however, it can also intensify fears or lead to an overinterpretation of risks.

From an ethical perspective, the question also arises as to how much genetic information is actually useful during pregnancy. Critics warn of potential “overdiagnosis,” in which even minor or unclear genetic variations could lead to intensive medical monitoring or unnecessary anxiety. Furthermore, there is the challenge of how this information can be communicated in a way that is both understandable and responsible during genetic counseling. Medicine is thus faced with the task of combining technological progress with careful, patient-centered application. The benefits of expanded diagnostics must always be weighed against potential psychological, social, and ethical consequences. It will be crucial to develop clear guidelines for handling extensive genetic findings so as not to overwhelm expectant parents, but rather to support them in a targeted and responsible manner.